<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">In Singapore, five individuals with COVID-19 were treated with lopinavir and ritonavir within 1–3 days of duration, but evidence of clinical use was ambiguous. Although fever developed within 1 to 3 days after the onset of lopinavir/ritonavir, in two patients disease progression was not prevented. The decrease in viral load indicated by the circulation threshold in lopinavir/ritonavir-treated and untreated individuals, and also nasopharyngeal swab results, were similar [
 <xref rid="bib57" ref-type="bibr">57</xref>]. In a retrospective study of 134 COVID-19 patients, it was found that improving symptoms and reduced viral load were not significantly different among the lopinavir/ritonavir treatment group (
 <italic>n</italic> = 52), arbidol treatment group (
 <italic>n</italic> = 34) and control group (
 <italic>n</italic> = 48) [
 <xref rid="bib58" ref-type="bibr">58</xref>].
</p>
